Objective
to report the 2 year results of a polymer-based zotarolimus-eluting stents (ZES) compared to biofreedom polymer-free biolimus A-g stents (DCS) in patients with high bleeding risk
Study
multicentre non-inferiority randomised trial
Population
patients undergoing PCI at high bleeding risk. They were treated with 1 month DAPT followed by single antiplatelet therapy (either aspirin or P2Y12 inhibitor) for 1 year. 77% were on SAPT at 2 years
Endpoints
composite of cardiac death, MI or stent thrombosis at 2 years
Conclusion
at 2 years follow-up the clinical outcomes of polymer-based (ZES) compared to polymer-free stents (DCS) were similar among patients with high-bleeding risk taking 1 month DAPT followed by SAPT
Windecker et al. J Am Coll Cardiol. Intv 2022;15:1153-63
